CB-183,315

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
0120112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Objectives The effects of surotomycin (CB-183,315, MK-4261), a bactericidal cyclic lipopeptide, and vancomycin, the current… (More)
Is this relevant?
2015
2015
OBJECTIVES Clostridium difficile infection (CDI) is the leading cause of hospital-acquired diarrhoea in developed countries… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
2015
2015
Surotomycin (CB-183,315), a cyclic lipopeptide, is in phase 3 clinical development for the treatment of Clostridium difficile… (More)
Is this relevant?
2014
2014
Surotomycin (CB-183,315) is an orally administered, minimally absorbed, selective bactericidal cyclic lipopeptide in phase 3… (More)
Is this relevant?
2012
2012
CB-183,315 is a novel lipopeptide antibiotic structurally related to daptomycin currently in phase 3 clinical development for… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
We evaluated the activity of CB-183,315 against Clostridium difficile, including strains that are resistant to fluoroquinolones… (More)
Is this relevant?
2012
2012
MICs of CB-183,315, a novel lipopeptide antibiotic, vancomycin, and metronidazole were determined for intestinal anaerobes and… (More)
Is this relevant?
2011
2011
Companies seeking approval for new biotech crops can now prepare their own environmental study or hire an outside contractor to… (More)
  • table 1
Is this relevant?